Cancer risk of immunosuppressants in manufacturing
- 1 October 2014
- journal article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 70 (1) , 122-124
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney TransplantationJournal of the American Society of Nephrology, 2010
- Immunosuppressive Therapy and Malignancy in Organ Transplant RecipientsDrugs, 2007
- Inhaled delivery of aerosolized cyclosporineAdvanced Drug Delivery Reviews, 2006
- Lung Deposition and Pharmacokinetics of Cyclosporine After Aerosolization in Lung Transplant PatientsPharmaceutical Research, 2003
- Immunosuppressive strategies in transplantationThe Lancet, 1999
- Cyclosporine induces cancer progression by a cell-autonomous mechanismNature, 1999
- Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimensThe Lancet, 1998
- Scientific and practical considerations for the development of occupational exposure limits (OELs) for chemical substancesRegulatory Toxicology and Pharmacology, 1992
- The effect of immunosuppressive chemotherapy on immune function in patients with malignant diseaseCancer, 1976
- Immunosurveillance and cancer: epidemiological evidence.BMJ, 1970